Overview

• Lilly said it will scale production through Indian contract manufacturers, and it has not disclosed partner names or timelines.
• A new manufacturing and quality site in Hyderabad will oversee local partners and provide technical capabilities across the network.
• Recruitment in Hyderabad begins immediately for engineers, chemists, analytical scientists, and quality control and assurance roles.
• The initiative is intended to expand supply of key Lilly medicines for obesity, diabetes, Alzheimer’s, cancer, and autoimmune conditions.
• The plan adds to more than $55 billion in global manufacturing commitments since 2020, including a recent $5 billion Virginia facility, with Reuters noting new U.S. tariffs on imported branded drugs and rising generic competition as context.